TREATMENT OF PARKINSON'S DISEASE WITH AMANTADINE AND LEVODOPA
| Autor: | R.B. Tattersall, Robin P. Knill-Jones, R.C.H Baxter, J. D. Parkes, G. Curzon, C. D. Marsden, Dorothy I. Vollum, P.J Knott |
|---|---|
| Rok vydání: | 1971 |
| Předmět: |
Levodopa
Movement disorders Parkinson's disease business.industry Parkinsonism Amantadine General Medicine Pharmacology medicine.disease Dihydroxyphenylalanine nervous system diseases chemistry.chemical_compound chemistry Anesthesia Edema medicine medicine.symptom business Livedo reticularis medicine.drug |
| Zdroj: | The Lancet. 297:1083-1087 |
| ISSN: | 0140-6736 |
| DOI: | 10.1016/s0140-6736(71)91834-4 |
| Popis: | 66 patients with Parkinson's disease were studied during a year of treatment. 26 patients were given amantadine, and 40 more disabled patients were given amantadine combined with levodopa. Amantadine gave significant and persistent benefit and is the treatment of choice for the slightly disabled patient. The additional effect of levodopa was apparent in moderately disabled patients, for whom combined amantadine/levodopa therapy was the preferred treatment. Side-effects of amantadine were livedo reticularis and leg œdema, whereas levodopa caused involuntary movements and gastrointestinal toxicity. Amantadine caused physiological alterations in skin blood-vessels, and although it may have a catecholamine-mobilising action it had, unlike levodopa, no effect on the low homovanillic-acid concentration of the cerebrospinal fluid in parkinsonism. The indications for surgical treatment of patients with Parkinson's disease are few. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|